ICCC FY 2020 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+11.8% YoY

Gross Profit

$7M44.7% margin

Operating Income

-$1M-9.0% margin

Net Income

-$1M-6.7% margin

EPS (Diluted)

$-0.14

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$3M

Stock-Based Comp.

$253,135

Balance Sheet

Total Assets

$40M

Total Liabilities

$12M

Stockholders' Equity

$28M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$14M	+11.8%
Gross Profit	$7M	$7M	+1.8%
Operating Income	-$1M	-$954,000	-44.7%
Net Income	-$1M	-$1M	+21.1%